logo
Nodal Staging in Lung Cancer
You Just Can't Call it Lung Cancer Anymore
The New Taxonomy of Lung Adenocarcinoma Stemming from a Multidisciplinary Integrated Approach
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer
Alpha1-Antitrypsin Deficiency Carriers, Serum Alpha 1-Antitrypsin Concentration, and Non-small Cell Lung Cancer Survival
Pharmacogenetic and Germline Prognostic Markers of Lung Cancer
Forced Expiratory Volume in One Second as a Prognostic Factor in Advanced Non-small Cell Lung Cancer
Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer
Significance of the Presence of Microscopic Vascular Invasion After Complete Resection of Stage I–II pT1-T2N0 Non-small Cell Lung Cancer and Its Relation with T-Size Categories
Surgical Procedures in the DANTE Trial, A Randomized Study of Lung Cancer Early Detection with Spiral Computed Tomography
Outcomes of Mediastinoscopy and Surgery with or without Neoadjuvant Therapy in Patients with Non-small Cell Lung Cancer Who are N2 Negative on Positron Emission Tomography and Computed Tomography
Radiologic Features, Staging, and Operability of Primary Lung Cancer in the Western Cape, South Africa
Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer
A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer
Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States
Potential Role of Platelet-Derived Growth Factor Receptor Inhibition Using Imatinib in Combination with Docetaxel in the Treatment of Recurrent Non-small Cell Lung Cancer
The Prognostic Value of the Simplified Comorbidity Score in the Treatment of Small Cell Lung Carcinoma
Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor Kinase Inhibitors
Giant Desmoid Tumor of the Chest Wall
Inherited Germline T790M Mutation and Somatic Epidermal Growth Factor Receptor Mutations in Non-small Cell Lung Cancer Patients
Dramatic Response to Pemetrexed in a Patient with Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma
Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer
Does the Addition of Vascular Endothelial Growth Factor Inhibitors to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Overcome T790M Acquired Resistance?
Histologic Type Definition in Clinical Trials on Advanced Non-small Cell Lung Cancer
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin as First-Line Chemotherapy
Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin as First-Line Chemotherapy
Genetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer: Erratum